title: Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
abstract: BACKGROUND
  Thrombolysis with recombinant tissue plasminogen activator (rt-PA) has gained international recognition, clinical outcomes following this thrombolytic therapy varied from patient to patient. Factors affecting clinical outcomes have not been well understood yet, so this retrospective case-control study aimed to investigate factors that may influence clinical outcomes of acute ischemic stroke treated with intravenous rt-PA.
  
  
  METHODS
  One hundred and one patients with acute ischemic stroke who received intravenous rt-PA thrombolysis within 4.5 hours from disease onset were included. Patients were divided into good or poor outcome group according to modified Rankin Scale (mRS) score, good outcome group: mRS score of 0-1; poor outcome group: mRS of 2-6. Stroke characteristics were compared between the two groups. Factors for stroke outcomes were analyzed via univariate analysis and Logistic regression.
  
  
  RESULTS
  Of the 101 patients studied, patients in good outcome group (n = 55) were significantly younger than patients in poor outcome group (n = 46, (62.82 ± 14.25) vs. (68.81 ± 9.85) years, P = 0.029). Good outcome group had fewer patients with diabetic history (9.09% vs. 28.26%, P = 0.012), fewer patients with leukoaraiosis (7.27% vs. 28.26%, P = 0.005) and presented with lower blood glucose level ((5.72 ± 1.76) vs. (6.72 ± 1.32) mmol/L, P = 0.012), lower systolic blood pressure level ((135.45 ± 19.36) vs. (148.78 ± 19.39) mmHg, P = 0.003), lower baseline NIHSS score (12.02 ± 5.26 vs. 15.78 ± 4.98, P = 0.002) and shorter onset-to-treatment time (OTT) ((2.38 ± 1.21) vs. (2.57 ± 1.03) hours, P = 0.044) than poor outcome group. Logistic regression analysis showed that absence of diabetic history (odds ratio (OR) 0.968 (95% CI 0.941-0.996)), absence of leukoaraiosis (OR 0.835 (95% CI 0.712-0.980)), lower baseline NIHSS score (OR 0.885 (95% CI 0.793-0.989)), lower pre-thrombolysis systolic blood pressure (OR 0.962 (95% CI 0.929-0.997)), and lower blood glucose level (OR 0.699 (95% CI 0.491-0.994)) before thrombolysis were significantly associated with better outcome.
  
  
  CONCLUSIONS
  Patients with no history of diabetes, no leukoaraiosis, low blood glucose level, low systolic blood pressure level and low baseline NIHSS score before thrombolysis have a better outcome.
authors.affiliation: Department of Neurology, Hospital of Jinjiang City, Jinjiang, Fujian 362000, China.
authors.forename: Yin-Hui
authors.initials: YH
authors.lastname: Huang
authors.affiliation: Department of Neurology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China.
authors.forename: Shi-Tu
authors.initials: ST
authors.lastname: Zhuo
authors.affiliation: Department of Neurology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China.
authors.forename: Ya-Fang
authors.initials: YF
authors.lastname: Chen
authors.affiliation: Department of Neurology, Mingxuan Hospital of Anxi County, Anxi, Fujian 362000, China.
authors.forename: Ming-Mei
authors.initials: MM
authors.lastname: Li
authors.affiliation: Department of Neurology, Hospital of Jinjiang City, Jinjiang, Fujian 362000, China.
authors.forename: You-Yu
authors.initials: YY
authors.lastname: Lin
authors.affiliation: Department of Neurology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China.
authors.forename: Mei-Li
authors.initials: ML
authors.lastname: Yang
authors.affiliation: Department of Neurology, Mingxuan Hospital of Anxi County, Anxi, Fujian 362000, China.
authors.forename: Zhen-Jie
authors.initials: ZJ
authors.lastname: Chen
authors.affiliation: Department of Neurology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China. Email: 251045413@qq.com.
authors.forename: Ruo-Wei
authors.initials: RW
authors.lastname: Cai
mesh_terms: D000368:Aged; D001794:Blood Pressure; D016022:Case-Control Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator